Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30254601 | 1.00 | HDAC1 (0.48) | HDAC1CYP3A4SMN1; SMN2PIK3CAPDE10A | |
| SCHEMBL8170822 | 0.84 | CYP3A4 (0.51) | HDAC1CYP3A4SMN1; SMN2PIK3CAPDE10A | |
| SCHEMBL2674207 | 0.83 | HDAC1 (0.45) | HDAC1CYP3A4SMN1; SMN2PIK3CAPDE10A | |
| SCHEMBL25272586 | 0.82 | CYP3A4 (0.47) | HDAC1CYP3A4SMN1; SMN2PDE10AKDM4E | |
| SCHEMBL2109473 | 0.82 | HDAC1 (0.52) | HDAC1CYP3A4SMN1; SMN2PIK3CAPDE10A | |
| SCHEMBL1114183 | 0.82 | HDAC1 (0.47) | HDAC1CYP3A4SMN1; SMN2PIK3CAPDE10A | |
| SCHEMBL28595917 | 0.82 | HDAC1 (0.54) | HDAC1CYP3A4SMN1; SMN2PIK3CAPDE10A | |
| SCHEMBL30440619 | 0.81 | HDAC1 (0.44) | HDAC1CYP3A4SMN1; SMN2PIK3CAPDE10A | |
| SCHEMBL25735607 | 0.81 | HDAC1 (0.44) | HDAC1CYP3A4SMN1; SMN2PIK3CAPDE10A | |
| SCHEMBL30440378 | 0.80 | HDAC1 (0.39) | HDAC1CYP3A4SMN1; SMN2PIK3CAPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | KINETA INC (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4444312-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| US-20240150358-A1 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. | 2024-05-09 | — | — | US | disclosed |
| WO-2023107552-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107552-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| EP-4161519-A1 | PURINES AND METHODS OF THEIR USE | Yumanity Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-3059238-B1 | FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | SHANGHAI YINGLI PHARM CO LTD (CN) | 2020-05-27 | — | — | EP | disclosed |
| US-9656996-B2 | Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2017-05-23 | — | — | US | disclosed |
| US-9656996-B2 | Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2017-05-23 | — | — | US | disclosed |
| US-20160244432-A1 | FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTCIAL COMPOSITION, AND USES THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2016-08-25 | — | — | US | disclosed |
| EP-3059238-A1 | FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | Shanghai Yingli Pharmaceutical Co. Ltd. (CN) | 2016-08-24 | — | — | EP | disclosed |
| EP-2593455-B1 | PURINE COMPOUNDS SELECTIVE FOR I3 P110 DELTA, AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2015-03-18 | — | — | EP | disclosed |
| EP-2593455-A1 | PURINE COMPOUNDS SELECTIVE FOR I3 P110 DELTA, AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| US-8293736-B2 | Purine compounds selective for PI3K P110 delta, and methods of use | F. HOFFMANN LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293736-B2 | Purine compounds selective for PI3K P110 delta, and methods of use | F. HOFFMANN LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293736-B2 | Purine compounds selective for PI3K P110 delta, and methods of use | F. HOFFMANN LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | US | disclosed |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | US | disclosed |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | US | disclosed |
| WO-2012007493-A1 | PURINE COMPOUNDS SELECTIVE FOR ΡI3Κ P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244432-A1 | FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTCIAL COMPOSITION, AND USES THEREOF | PIK3CA, PIK3CD, PIK3R5 | HDAC1 344/4885CYP3A4 340/4885SMN1; SMN2 4592/4885 |
| US-20240150358-A1 | PURINES AND METHODS OF THEIR USE | PNP, NUDT1, HPRT1 | HDAC1 3695/4885CYP3A4 2418/4885SMN1; SMN2 103/4885 |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CG | HDAC1 3977/4885CYP3A4 1297/4885SMN1; SMN2 2114/4885 |
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | TDP1, TDP2, PIKFYVE | HDAC1 3403/4885CYP3A4 3989/4885SMN1; SMN2 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.